Lipid Particle Composition for Selective T-Cell Tumor Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods struggle to deliver therapeutic or diagnostic agents specifically to T-cell malignant tumor cells due to their surface antigens being indistinguishable from normal T cells, making targeted treatment and diagnosis challenging.
Innovation Solution
A lipid particle composition containing specific lipids (represented by formulas I and II) is used to encapsulate therapeutic or diagnostic agents, allowing selective delivery to T-cell malignant tumor cells through endocytosis, while minimizing incorporation into normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional delivery methods are used, then therapeutic or diagnostic agents can be delivered to cells, but specific delivery to T-cell malignant tumor cells cannot be achieved due to indistinguishable surface antigens
Solution Approach 1:
The patent applies local quality by modifying the lipid particle surface with specific ligands that locally recognize and bind to unique markers on T-cell malignant tumor cells. This localized functional differentiation allows the delivery system to distinguish between malignant and normal cells despite their overall similar surface antigen profiles, enabling selective delivery to the target cells.
Solution Approach 2:
The patent employs parameter changes by adjusting the lipid composition, charge, and surface properties of the delivery particles to optimize their interaction with T-cell malignant tumor cells. By modifying parameters such as lipid ratio, particle size, and surface functionalization, the system achieves enhanced specificity and uptake by malignant cells while minimizing interaction with normal T cells.
2Productivity
If lipid particles are used to encapsulate therapeutic agents, then delivery efficiency improves, but selectivity for malignant tumor cells versus normal cells decreases
Solution Approach 1:
The patent uses composite materials by combining specific lipid components with functional ligands and surface modifiers on the lipid particle. This composite structure maintains the efficient cell membrane fusion and uptake properties of lipid particles while adding selective recognition capabilities through the integrated ligand system, thereby achieving both high delivery efficiency and cell-type selectivity.
Solution Approach 2:
The patent introduces intermediary molecules (specific ligands and surface functional groups) on the lipid particle that act as mediators between the delivery system and the target cells. These intermediaries enable selective binding to T-cell malignant tumor cells while the lipid core maintains efficient cellular uptake, thus resolving the contradiction between delivery efficiency and selectivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lipid particle composition efficiently delivers therapeutic agents like cytocidal genes (e.g., RNA) or diagnostic agents to T-cell malignant tumor cells, reducing or detecting them effectively while sparing normal cells, thus providing targeted treatment and diagnosis.
Implementation Method 1
The lipid particle is incorporated into the T-cell malignant tumor cell
Data Source
AI summary
According to one embodiment, a composition is for delivering an objective substance to the T-cell malignant tumor cell. The composition contains a substance delivery carrier. The substance delivery carrier has a lipid particle, and the objective substance encapsulated in the lipid particle. The lipid particle contains, as constituents thereof, at least a first lipid represented by formula (I) and a second lipid represented by formula (II).